{
  "abstract": "The addition of entinostat, a histone deacetylase inhibitor, to exemestane has demonstrated improved progression-free survival (PFS) in hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) following endocrine therapy failure in the EOC103A3101 randomized trial (NCT03538171). This study reports long-term overall survival (OS) results. In this study, 354 patients with HR + /HER2- ABC that had recurred or progressed after endocrine therapy were randomized (2:1) to receive entinostat plus exemestane (n = 235) or placebo plus exemestane (n = 119). After a median follow-up of 31.8 months, the median OS was 38.6 months (95% confidence interval [CI]: 29.6-44.0) in the entinostat-exemestane group versus 29.2 months (95% CI: 22.5-41.6) in the placebo-exemestane group (hazard ratio [HR] 0.83, 95% CI: 0.62-1.10, P = 0.184). The entinostat-exemestane group demonstrated more pronounced OS benefits when adjusting subsequent antitumor therapies such as cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, or the combination of endocrine therapy, CDK4/6 inhibitors, and chemotherapy. The sensitivity analysis based on the per-protocol set showed more significant OS benefits. The median time to post-discontinuation chemotherapy and chemotherapy-free survival in the entinostat-exemestane group were 11.7 and 9.3 months, respectively, compared to 6.8 and 5.6 months in the placebo-exemestane group (both P < 0.05). Grade ≥3 treatment-emergent adverse events occurred in 65.5% of patients in the entinostat-exemestane group, without new safety signals observed. In conclusion, among patients with HR + /HER2- ABC after endocrine therapy failure, entinostat plus exemestane was associated with a numerically longer OS, with an acceptable safety profile.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.",
    "Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.",
    "Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.",
    "Department of Galactophore, Liaoning Cancer Hospital & Institute, Shenyang, China.",
    "Department of Oncology, The First Hospital of Jilin University, Changchun, China.",
    "Department of Galactophore, Hunan Cancer Hospital, Changsha, China.",
    "Department of Galactophore, Linyi Cancer Hospital, Linyi, China.",
    "Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.",
    "Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.",
    "Department of Breast Oncology, Beijing Cancer Hospital, Beijing, China.",
    "Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.",
    "Department of Breast and Thyroid Oncology, Affiliated Hospital of Jining Medical Universtiy, Jining, China.",
    "Department of Medical Oncology, Run Run Shaw Hospital, Affiliated Hospital of Zhejiang University, Hangzhou, China.",
    "Taizhou EOC Pharma Co. Ltd., Taizhou, China.",
    "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xubingheBM@163.com.",
    "State Key Laboratory of Molecular Oncology and Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xubingheBM@163.com."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 18,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jiani Wang"
    },
    {
      "affs": [
        1
      ],
      "name": "Qingyuan Zhang"
    },
    {
      "affs": [
        2
      ],
      "name": "Xichun Hu",
      "orcid": "0000-0001-6148-9186"
    },
    {
      "affs": [
        3
      ],
      "name": "Tao Sun"
    },
    {
      "affs": [
        4
      ],
      "name": "Wei Li"
    },
    {
      "affs": [
        5
      ],
      "name": "Quchang Ouyang"
    },
    {
      "affs": [
        6
      ],
      "name": "Jingfen Wang"
    },
    {
      "affs": [
        7
      ],
      "name": "Zhongsheng Tong"
    },
    {
      "affs": [
        8
      ],
      "name": "Min Yan",
      "orcid": "0000-0002-3911-748X"
    },
    {
      "affs": [
        9
      ],
      "name": "Huiping Li"
    },
    {
      "affs": [
        10
      ],
      "name": "Xiaohua Zeng"
    },
    {
      "affs": [
        11
      ],
      "name": "Changping Shan"
    },
    {
      "affs": [
        12
      ],
      "name": "Xian Wang"
    },
    {
      "affs": [
        2
      ],
      "name": "Jian Zhang"
    },
    {
      "affs": [
        1
      ],
      "name": "Yue Zhang"
    },
    {
      "affs": [
        3
      ],
      "name": "Liang Zhang"
    },
    {
      "affs": [
        13
      ],
      "name": "Hongyan Shang"
    },
    {
      "affs": [
        14,
        15
      ],
      "name": "Binghe Xu",
      "orcid": "0000-0003-4195-337X"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/cc4k0dk6tdkg8.bib",
  "cited_by": 0,
  "doi": "10.1038/s41392-026-02899-8",
  "fulltext_url": "https://europepmc.org/articles/PMC13680365",
  "id": "cc4k0dk6tdkg8",
  "issns": [
    "2095-9907",
    "2059-3635"
  ],
  "landing_url": "https://europepmc.org/article/MED/42897132",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "QH301-705.5"
    ],
    [
      "lcc",
      "R"
    ],
    [
      "openalex",
      "2740|Advanced Breast Cancer Therapies"
    ]
  ],
  "openalex": "W7222955872",
  "pdf_url": "https://europepmc.org/articles/PMC13680365?pdf=render",
  "pmcid": "PMC13680365",
  "pmid": "42897132",
  "published": "2026-10-20",
  "publisher": "Nature Publishing Group",
  "ris": "https://research.draconitic.com/paper/cc4k0dk6tdkg8.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:32Z",
      "native_id": "MED:42897132",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42897132"
    },
    {
      "first_seen": "2026-10-30T13:46:32Z",
      "native_id": "3fb3947c3798404eb88deab90bc5fcc9",
      "source": "doaj",
      "url": "https://doi.org/10.1038/s41392-026-02899-8"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Advanced Breast Cancer Therapies",
      "subfield": "general"
    }
  ],
  "title": "Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial.",
  "title_text": "Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:46:32Z",
  "url": "https://research.draconitic.com/paper/cc4k0dk6tdkg8",
  "venue": "Signal transduction and targeted therapy",
  "versions": []
}